**Ultrasound-assisted synthesis of novel** **1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents**

Mohamed F. Madya,b,\*, Ghada E.A. Awadc, Kåre B. Jørgensena,\*

a*Department of Mathematics and Natural Sciences, Faculty of Science and Technology, University of Stavanger, N-4036 Stavanger, Norway*

b*Department of Green Chemistry, National Research Centre, Dokki, Cairo 12622, Egypt*

c*Chemistry of Natural and Microbial Products, National Research Center, Dokki, Cairo 12622, Egypt*

\*) Corresponding author: Kåre B. Jørgensen, phone: +47 51832306; fax: +47 51831750; e-mail: [kare.b.jorgensen@uis.no](mailto:kare.b.jorgensen@uis.no)

\*) Corresponding author: Mohamed F. Mady, phone: +47 91256933; fax: +47 51831750; e-mail: mohamed\_madii@yahoo.com

**Keywords:** One-pot reaction, Sonication, Click chemistry, Antioxidant activity, Antimicrobial activity, Diaryl sulfone

**Abstract:**

A series of 1,2,3-triazoles coupled diaryl sulfone containing compounds were synthesized by the copper-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction in benign solvents under ultrasound irradiation. *In situ* formation of azides from -bromoketones together with the CuAAC reaction in one pot allowed safe handling and good availability of azides for the development of a small library of compounds. The sonication reduced reaction time and increased yields compared to otherwise same conditions. All synthesized compounds were evaluated for antibacterial, antifungal and antioxidant activities. Compounds **3b**, **6b** and **9e-9g** were found to be the most potent antifungal agents with minimal inhibitory concentration (MIC) at 25 µg/mL; moreover other compounds revealed good to moderate antimicrobial activity. Compound **8e** showed an excellent antioxidant activity using a DPPH free radical scavenging assay.

1. **Introduction**

Antimicrobial agents are fundamental medicines for human and animal health and welfare, and are considered "miracle drugs" to treat infections caused by bacteria, fungi, parasites, and viruses. The discovery of different types of microorganisms explained the main reasons for infection diseases [1,2]. According to the World Health Organization (WHO) the infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. About 440 000 new cases of multidrug-resistant tuberculosis (MDR-TB) emerge annually, causing at least 150 000 deaths. In addition, a high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA) [3,4]. The antioxidants that scavenge reactive oxygen species (ROS) may be of efficient value in preventing the onset and propagation of oxidative diseases such as autoimmune diseases, cardiovascular diseases and neurovascular diseases. A balance between ROS and antioxidants is necessary for proper physiological function [5]. These health risks encourage the development and modification of antioxidants and antimicrobial drugs by the design and synthesis of new chemical compounds with high efficiency, low toxicity and broad spectrum.

The importance of sulfones in medicinal chemistry is well recognized. In particular, organosulfone derivatives have been used as drugs due to their high potential as antibacterial, antifungal, anti-nociceptive and anti-inflammatory agents such as Lasix, Aquazide h, and Sulfadimidine (Figure 1)[6-14]. Furthermore, the diaryl sulfone function was found a potent antimicrobial agent [15]. Some well-known medicines are available in the market, for example Dapsone [16] andPromine [17];as shown in Figure 1. Noticeably, the combination of a diarylsulfone ring system with various types of heterocyclic analogues has shown significant biological activities [18-22].

The 1,2,3-triazole unit has received great interest and special attention because of its wide and extensive medicinal applications, such as antibacterial [23],antifungicidal [24], antiviral [25], anti-oxidant [26] or anti-inflammatory agents [27]. 1,4-Disubstituted 1,2,3-triazoles are obtainable in high yields by the copper-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction often used in the click chemistry concept which play an efficient role in drug discovery applications. This reaction proceeds with great efficiency and selectivity in aqueous media [28,29].

The above mentioned facts encouraged us to continue our exploration of diaryl sulfone derivatives [30-32], in the pursuit of novel compounds with antimicrobial or antioxidant activities with the potential of becoming new drugs. Combining the activities of the diaryl sulfone group and the 1,2,3-triazole we have designed and synthesized mono and bis-1,2,3-triazole derivatives of the diaryl sulfone scaffold, as outlined in Figure 2, by installing triple bonds on the scaffold and clicking on new groups while forming 1,2,3-triazoles with the CuAAC reaction. Synthesis under ultrasound irradiation was compared to silent conditions at the same temperature to explore the effect of sonication on the reactions. All synthesized compounds were evaluated for their antioxidant, antibacterial and antifungal activities, and also their minimum inhibitory concentration (MIC).



**Figure 1.** Examples ofdrugs molecules containing the diaryl sulfone moiety or sulfonyl groups.



**Figure 2.** The designed bioactive scaffold has three variable parts, while containing 1,2,3-triazole and diaryl sulfone as a main backbone.

1. **Results and Discussion** 
   1. ***Chemistry***

The synthesis work is outlined in Scheme 1. *Route A* is a stepwise approach that allow click coupling of two different azides for more diversity, while *route B* saves one step by first introducing both alkynes and then form both triazoles simultaneously from the same azide. The first step in the construction of our scaffold were the preparation of the key aryl sulfone intermediates **2a,b** containing a terminal alkyne by ultrasound mediated Barbier-type propargylation of the corresponding carbonyl compounds **1a,b** [30]. Proargyl bromide in dry THF in the presence of Zinc, and the Lewis acid ZnBr2 as an additive, afforded the homopropargylic alcohol with high yields and regioselectivity above 99%. Times and yields of the reactions under both ultrasound irradiation and silent conditions are tabulated in Table 1. Ultrasound irradiation improved the yield and decreased the reaction time compared to the silent conditions.

Next, we investigated the scope and the generality of the CuAAC reaction [33]. The commercially available benzyl azide was applied on alkynes **2a,b**, and later **4a,b** and **5a,b,** affording excellent yields of 1,4-disubstituted 1,2,3-triazoles (**3a,b** and **6a,b**) under both ultrasound irradiation and silent conditions (Scheme 1).



**Scheme 1**. Synthesis of mono and bis-1,2,3-triazoles by stepwise introduction of alkyne followed by the CuACC reaction (*Route A*) for increased diversity, or simultaneous bis-1,2,3-triazole formation (*Route B*) for increased efficiency.

**Table 1**

Synthesis of homopropargyl alochols **2a,b** by the Barbier-type reaction (Scheme 1).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Entry | Starting material | Product | Ultrasound irradiation | | Stirring conditions | |
| Time (h) | Yield (%) | Time (h) | Yield (%) |
| 1 | **1a** | **2a** | 1 | 89 | 12 | 73 |
| 2 | **1b** | **2b** | 1.5 | 80 | 12 | 70 |

**Table 2**

Synthesis of 1,2,3-triazoles **3a,b**; **6a,b** by the CuAAC reaction (Scheme 1).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Entry | Starting material | Product | Ultrasound irradiation | | Stirring conditions | |
| Time (min) | Yield (%) | Time (h) | Yield (%) |
| 1 | **2a** | **3a** | 20 | 97 | 1 | 85 |
| 2 | **2b** | **3b** | 20 | 91 | 1 | 76 |
| 3 | **4a** | **6a** | 30 | 95 | 2 | 80 |
| 4 | **4b** | **6b** | 30 | 93 | 2 | 81 |
| 5 | **5a** | **6a** | 30 | 90 | 4 | 79 |
| 6 | **5b** | **6b** | 30 | 86 | 4 | 78 |

**Table 3**

Synthesis of alkynes **4a,b** and bis-alkynes **5a,b** by propargylation of the corresponding alochols (Scheme 1).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Entry | Starting material | Product | Ultrasound irradiation | | Stirring conditions | |
| Time (min) | Yield (%) | Time (h) | Yield (%) |
| 1 | **2a** | **5a** | 30 | 99 | 2 | 90 |
| 2 | **2b** | **5b** | 30 | 90 | 2 | 85 |
| 3 | **3a** | **4a** | 30 | 80 | 2 | 70 |
| 4 | **3b** | **4b** | 30 | 78 | 2 | 66 |

The synthesis of mono triazoles **3a,b** involved the click reaction between propargyl alcohol **2a,b** and benzyl azideby copper sulfate and sodium ascorbate at 25-30 oC in *tert*-butanol:water 2:1 under ultrasound irradiation compared to simple stirring [33] (Table 2). Along *Route A* in Scheme 1 the hydroxyl group in aryl sulfones **3a,b** was propargylated with propargyl bromide in dry DMF and sodium hydride (NaH) at -20 oC under sonication or stirring, affording the O-propargylated isomer **4a,b** in high yields (Table 3) with no trace of allene formation. The O-propargylated products were reacted with benzyl azide using the click conditions as described in the experimental section, to formbis-triazoles **6a,b** in excellent yields in short time. Along *route B*, outlined in Scheme 1, hydroxyalkynes **2a,b** were first propargylated (Table 3) to bisalkynes **5a,b**, before reaction with two equivalents of azide under ultrasound irradiation gave bis-triazoles **6a,b** in better yields than by silent conditions. It is clear from the results listed in Table 2, that the 1,3-dipolar cycloaddition reaction performed better under ultrasound irradiation. While the reactions under silent conditions needed 1-4 h for completion with yields between 76% and 85%, ultrasound irradiation gave yields between 86% and 97% after just 20-30 min.

To further expand the novel 1,2,3-triazole series a variety of -azido ketones was desired. However, it has been reported that the 1,3-dipolar cycloaddition of α-azido ketones with alkynes were difficult because α-azido ketones are often unstable to heat and light. In addition isolation and purification of the α–azido ketones were difficult due to incomplete conversion [34]. Therefore, in situ preparation would provide an efficient way to handle them safely. Multicomponent reactions (MCRs) have significant advantages in the synthesis of drug libraries by efficient introduction of molecular complexity with good atom economy [35].

As part of our program aimed to use green chemistry tools in organic synthesis [30-32], we decided to develop a one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles from α–bromoketones, sodium azide, and alkynes. The model reaction, as shown in Table 4, was performed in the presence of different types of solvents, copper sulfate and sodium ascorbate at 25-30 oC under ultrasound irradiation to find optimum conditions.

**Table 4**

Effect of solvents on the one-pot synthesis of keto1,2,3-triazoles from *in situ* formed azides.a

|  |  |  |  |
| --- | --- | --- | --- |
|  | | | |
| Entry | Solvent | Time (h) | Yieldb (%) |
| 1 | DMSO | 12 | None |
| 2 | DMF | 12 | None |
| 3 | *t*-BuOH | 12 | None |
| 4 | H2O | 12 | 10 |
| 5 | PEGc | 12 | 8 |
| 6 | PEG/H2O (1:1) | 12 | 25 |
| 7 | H2O/*t*-BuOH (1:1) | 12 | 33 |
| 8 | H2O/*t*-BuOH (2:1) | 5 | 60 |
| 9 | H2O/*t*-BuOH (3:1) | 1 | 90 |

aReaction conditions: **7a** (1.0 equiv.), NaN3 (1.2 equiv.), **2a** (1.0 equiv.), CuSO4.5H2O (0.1 equiv.) and Na ascorbate (0.3 equiv.); bIsolated yields; cPEG= Poly(ethylene glycol), average mol wt= 200.

The best results were obtained when using H2O/*t*-BuOH (3:1) as an efficient medium for the one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles (Table 4, entry 9).

A plausible mechanism for the formation of 1,2,3-triazoles is initial formation of the α-azido ketone as an intermediate, as was observed when reacting equimolar quantities of α-halo ketone derivative **7a** with sodium azide without alkyne **2a** under identical conditions. Subsequently, 1,3-dipolar cycloaddition of α-azido ketone and terminal alkyne **2a** afforded the desired product **8a.** In general, we found that the new solvent system, H2O/*t*-BuOH (3:1) afforded keto 1,2,3-triazoles in good yield within a short time compared to the other solvents.

With the optimized conditions in hand, we prepared a range of mono and bis-keto triazoles containing aryl sulphone groups *via* the one-pot click reaction as shown in Tables 5 and 6.

**Table 5**

One-pot synthesis of triazoles **8a-h**.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | |
| Entry | Starting material | X | R | Product | Ultrasound irradiation | | Stirring  conditions | |
| Time (min) | Yield (%) | Time (h) | Yield (%) |
| 1 | **7a** | SO2Ph | H | **8a** | 60 | 90 | 4 | 80 |
| 2 | **7b** | F | H | **8b** | 30 | 96 | 3 | 83 |
| 3 | **7c** | Br | H | **8c** | 30 | 94 | 3 | 85 |
| 4 | **7d** | H | H | **8d** | 30 | 95 | 3 | 84 |
| 5 | **7a** | SO2Ph | Me | **8e** | 60 | 89 | 4 | 79 |
| 6 | **7b** | F | Me | **8f** | 30 | 94 | 3 | 81 |
| 7 | **7c** | Br | Me | **8g** | 30 | 91 | 3 | 80 |
| 8 | **7d** | H | Me | **8h** | 30 | 92 | 3 | 81 |

**Table 6**

One-pot synthesis of bistriazoles **9a-h**.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | | |
| Entry | Starting material | X | R | Product | Ultrasound irradiation | | Stirring  conditions | |
| Time (min) | Yield (%) | Time (h) | Yield (%) |
| 1 | **7a** | SO2Ph | H | **9a** | 45 | 85 | 4 | 76 |
| 2 | **7b** | F | H | **9b** | 45 | 90 | 3 | 80 |
| 3 | **7c** | Br | H | **9c** | 45 | 89 | 3 | 87 |
| 4 | **7d** | H | H | **9d** | 45 | 88 | 3 | 78 |
| 5 | **7a** | SO2Ph | Me | **9e** | 60 | 83 | 4 | 75 |
| 6 | **7b** | F | Me | **9f** | 45 | 88 | 3 | 79 |
| 7 | **7c** | Br | Me | **9g** | 45 | 85 | 3 | 74 |
| 8 | **7d** | H | Me | **9h** | 45 | 86 | 3 | 75 |

All compounds were purified by silica gel column chromatography and were fully characterized by IR, 1H nuclear magnetic resonance (NMR), 13C NMR and high-resolution mass spectral (HRMS) analyses. Furthermore, the structures **9a-c; 9e-g** were confirmed by elemental analysis (see experimental section). For example The IR spectrum of **8d** displayed a strong band at about 1701 cm-1 indicating the presence of a ketone group. The 1H NMR spectra of **8d** showed a distinct singlet signal at δ 7.76 ppm for triazolyl C5-H proton. 13C NMR also displayed two distinct signals at δ 124.9 ppm and δ 192.3 ppm corresponding to the triazolyl C5 and the carbonyl carbon respectively. The mass spectrum of this compound exhibits the molecular ion peak at *m/z =* 470 [M+Na]+, which is in agreement with the calculated mass. As outlined in Table 5, the one-pot three component synthesis of 1,2,3-triazoles carried out under ultrasonic irradiation gave excellent yields and shorter reaction times compared to the silent reaction. For example, the product **8d** took about 3 h for completion under silent conditions and the yield of the product was 84%. In comparison, under ultrasonic irradiation, the reaction time was 30 min and the yield 95%.

* 1. ***Biological activities***
     1. *Antimicrobial activity*

The antimicrobial activities of all the synthesized triazole linked diaryl sulfone derivatives were tested by the presence or absence of inhibition zones and zone diameter against ten microbial strains: Four Gram-positive bacteria (*Staphelococcus aureus* ATCC 29213*, Bacillus subtilis* ATCC663, *Bacillus megaterium* ATCC 9885 and *Sarcina lutea*); three Gram-negative bacteria (*Klebsiella pneumonia* ATCC13883*, Pseudomonas aeruginosa* ATCC2795 and *Escherichia coli* 25922); two yeasts (*Candida albicans* NRRL Y-477 and *Saccharomyces cervesia*) and one fungi (*Aspergillus niger*). The results from the evaluation of antimicrobial effects are summarized in Table 7. The compounds were compared with the standard antibacterial drug Ciprofloxacin and the yeast/antifungal drug Clotrimazole.

It was found that compounds **3a,b**; **6a,b**; **8a-8h**; **9a-9h** showed variable antibacterial activity against Gram-positive and Gram-negative bacteria. For example, compound **3a** showed a zone inhibition of 19 mm against *Staphelococcus aureus* ATCC 29213 and compounds **3a**; **8b-8d**; **9a,9b** displayed zone inhibitions in the range of 19-20 mm against *Sarcina lutea.* Other compounds showed moderate to poor inhibition against both Gram-positive and Gram-negative bacteria.

The Minimum inhibitory concentration (MIC) of all compounds was also screened as listed in Table 8. All tested compounds showed high MICs, ranging from 50 to 200 µg/mL, against Gram-positive and Gram-negative bacteria compared to the standard drug Ciprofloxacin. Unfortunately, none of the tested compound presented any significant activity against yeast.

Antifungal activity was screened against *Aspergillus niger.* The compounds showed good to excellent antifungal activities against the strain, comparable to the standard drug Clotrimazole as shown in Table 7.

Compounds **3b**, **6b**, **8d**, **8e**, **8h**, **9b** and **9d-g** showed the highest zone inhibition against *A. niger* in the range 32-34 mm. The MICs of the new compounds against this pathological strain are tabulated in Table 8. Compounds **3b**, **6b** and **9e-g** were found most effective against the fungal strain with the lowest MIC of 25 µg/mL, similar to Clotrimazole.

**Table 7**

Antimicrobial activity expressed as inhibition diameter zones in millimeters (mm) of novel triazoles against the pathological strains based on well diffusion assay.a

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | *Gram-positive bacteria* | | | |  | *Gram-negative bacteria* | | |  | *Yeast* | |  | *fungi* |
| *S. aureus*  ATCC 29213 | *B. subtilis*  ATCC  6633 | *B. megaterium*  ATCC  9885 | *S. lutea* |  | *K. peneumoniae* ATCC  13883 | *P. aeroginosa*  ATCC  27953 | *E. coli*  ATCC  25922 |  | *C. albicans*  NRRL Y-477 | *S. cervesia* |  | *A. niger* |
| **3a** | 19 | 17 | 14 | 20 |  | 23 | 20 | 19 |  | 19 | 17 |  | 30 |
| **3b** | 22 | 16 | 17 | 23 |  | 24 | 23 | 22 |  | 19 | 16 |  | 32 |
| **6a** | 14 | 15 | 14 | 17 |  | 17 | 18 | 19 |  | 18 | 18 |  | 30 |
| **6b** | 14 | 14 | 17 | 17 |  | 15 | 19 | 18 |  | 16 | 14 |  | 34 |
| **8a** | 17 | 20 | 15 | 22 |  | 19 | 17 | 17 |  | 15 | 16 |  | 28 |
| **8b** | 14 | 19 | 17 | 20 |  | 15 | 19 | 14 |  | 13 | N.A. |  | 32 |
| **8c** | 22 | 14 | 19 | 20 |  | 24 | 25 | 22 |  | 20 | 17 |  | 30 |
| **8d** | 14 | 19 | N.A. | 20 |  | 22 | 20 | 17 |  | 12 | N.A. |  | 29 |
| **8e** | N.A.b | N.A. | 17 | 14 |  | 18 | 15 | 19 |  | 15 | 17 |  | 32 |
| **8f** | 17 | 19 | 17 | 21 |  | 19 | 22 | 19 |  | 15 | N.A. |  | 32 |
| **8g** | 17 | 17 | N.A. | N.A. |  | 19 | 19 | 17 |  | 15 | 14 |  | 20 |
| **8h** | 18 | 19 | 15 | 22 |  | 13 | 19 | 14 |  | 15 | 14 |  | 32 |
| **9a** | 17 | 14 | N.A. | 19 |  | 13 | 14 | N.A. |  | 14 | N.A. |  | 20 |
| **9b** | 26 | 19 | 17 | 20 |  | 16 | 15 | 14 |  | 22 | 19 |  | 32 |
| **9c** | 17 | 17 | 20 | 22 |  | N.A. | N.A. | 17 |  | 21 | 20 |  | 20 |
| **9d** | 24 | 17 | 20 | 24 |  | 15 | 23 | 20 |  | 23 | 22 |  | 20 |
| **9e** | 14 | 14 | 22 | 25 |  | 19 | 19 | 17 |  | 15 | 14 |  | 34 |
| **9f** | 27 | 15 | 17 | 26 |  | 26 | 27 | 25 |  | N.A. | 15 |  | 34 |
| **9g** | 24 | 14 | 23 | 24 |  | 26 | 26 | 24 |  | 15 | 14 |  | 32 |
| **9h** | N.A. | 16 | 17 | 17 |  | 23 | 19 | 21 |  | 15 | 16 |  | 28 |
| Ciprofloxacin | 20 | 22 | 24 | 20 |  | 25 | 24 | 23 |  | N.A. | N.A. |  | N.A. |
| Clotrimazole | N.A. | N.A. | N.A. | N.A. |  | N.A. | N.A. | N.A. |  | 30 | 31 |  | 33 |

*a* The experiment was carried out in triplicate and the average zone of inhibition was calculated.

*b* N.A. (no activity)

**Table 8**

Minimum inhibitory concentration (µg/mL) against the pathological strains based on two folds serial dilution technique.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Entry | *S. aureus*  ATCC 29213 | *B. subtilis*  ATCC  6633 | *B. megaterium*  ATCC  9885 | *S. lutea* | *K. peneumoniae* ATCC  13883 | *P. aeroginosa*  ATCC  27953 | *E. coli*  ATCC  25922 | *C. albicans*  NRRL Y-477 | *S. cervesia* | *A. niger* |
| **3a** | 200 | 200 | N.A. | 200 | 200 | 200 | 200 | 200 | 200 | 50 |
| **3b** | 200 | 200 | 200 | 200 | 100 | 200 | 200 | 200 | 200 | 25 |
| **6a** | N.A. | N.A. | N.A. | 200 | 200 | 200 | 200 | 200 | 200 | 50 |
| **6b** | N.A. | N.A. | 200 | 200 | N.A. | 200 | 200 | 200 | N.A. | 25 |
| **8a** | 200 | 200 | N.A. | 100 | 200 | 200 | N.A. | N.A. | 200 | 50 |
| **8b** | N.A. | 200 | 200 | 200 | N.A. | 200 | N.A. | N.A. | N.A. | 50 |
| **8c** | 200 | N.A. | 200 | 200 | 100 | 100 | 200 | 200 | 200 | 50 |
| **8d** | N.A. | 200 | N.A. | 200 | 200 | 200 | 200 | N.A. | N.A. | 100 |
| **8e** | N.A. | N.A. | 200 | N.A. | 200 | N.A. | 200 | N.A. | 200 | 50 |
| **8f** | 200 | 200 | 200 | 200 | 200 | 200 | 200 | N.A. | N.A. | 50 |
| **8g** | 200 | 200 | N.A. | N.A. | 200 | 200 | 200 | N.A. | N.A. | 200 |
| **8h** | 200 | 200 | N.A. | 200 | N.A. | 200 | N.A. | N.A. | N.A. | 50 |
| **9a** | 200 | N.A. | N.A. | 200 | N.A. | N.A. | N.A. | N.A. | N.A. | 100 |
| **9b** | 100 | 200 | 200 | 200 | 200 | N.A. | N.A. | 200 | 200 | 50 |
| **9c** | 200 | 200 | 200 | 200 | N.A. | N.A. | 200 | 200 | 200 | 200 |
| **9d** | 100 | 200 | 200 | 100 | 100 | 100 | 200 | 200 | 200 | 200 |
| **9e** | N.A. | N.A. | 200 | 100 | 200 | 200 | 200 | N.A. | N.A. | 25 |
| **9f** | 100 | N.A. | 200 | 50 | 100 | 100 | 100 | N.A. | N.A. | 25 |
| **9g** | 100 | N.A. | 100 | 100 | 100 | 100 | 100 | N.A. | N.A. | **25** |
| **9h** | N.A. | N.A. | 200 | 200 | 200 | 200 | 200 | N.A. | 200 | 50 |
| Ciprofloxacin | 25 | 25 | 25 | 25 | 25 | 25 | 25 | N.A. | N.A. | N.A. |
| Clotrimazole | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | 25 | 25 | 25 |

* + 1. *Structure-activity relationships*

The results of the antimicrobial screening revealed that the backbone built from ketone **1b** (R= Me in Figure 2), had consistently better antifungal activity than molecules based on the aldehyde **1a** against *A. niger*, and some are as potent as standard drugs. The modifications added to the hydroxyl group through the ether link at R’ (**6** compared to **3**, and **9** compared to **8**), with a benzyl group or keto benzene derivatives as R’’, reduced the activity of the less active compounds but had little impact when R=Me. In addition we found that replacement of the *para*-hydrogen of keto benzene **9h** by phenylsulfonyl, fluoro and bromo functions, as in **9e-g** respectively, increased the antimicrobial activity.

* + 1. *Antioxidant activity*

The antioxidant activity of all synthesized compounds were measured against 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical. The DPPH procedure is one of the most effective methods for evaluating the concentration of radical scavenging materials active by a chain-breaking mechanism [36]. DPPH radical scavenging activity evaluation is a rapid and convenient assay for screening the antioxidant activities of products. Table 9 summarizes the radical scavenging activities of all compounds, compared to the synthetic antioxidant 4-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)- methoxy)aniline (BHT). It has been reported that the aryl sulfone moiety enhance the antioxidant activity through enhanced expression of antioxidant genes, and this new class of powerful antioxidants might be a potent treatment for Parkinson's disease [37,38]. Several compounds showed an excellent free radical scavenging activity. Compound **8e**, with R’= H and R’’ containing another diaryl sulfone moiety, was the strongest radical scavenger with an IC50 value of 20 μg/mL. Moreover compound **8a** showed an excellent radical scavenging activity with IC50 at 74 μg/mL. Compounds **9h**, **9c**, **9f** and **9d** also showed very good scavenging activities with IC50 at 125, 150, 150 and 175 μg/mL, respectively. The other compounds also showed scavenging activity, but demanded higher concentrations of the compounds.

**Table 9**

Anti-oxidant activity measured as IC50 by the DPPH procedure.

|  |  |
| --- | --- |
| IC50 (μg/mL) | Compounds |
| 200 | **3a** |
| 600 | **3b** |
| 500 | **6a** |
| 600 | **6b** |
| 74 | **8a** |
| 275 | **8b** |
| 500 | **8c** |
| 425 | **8d** |
| 20 | **8e** |
| 425 | **8f** |
| 800 | **8g** |
| 600 | **8h** |
| 600 | **9a** |
| 275 | **9b** |
| 150 | **9c** |
| 175 | **9d** |
| 600 | **9e** |
| 150 | **9f** |
| N.A. | **9g** |
| 125 | **9h** |
| 50 | **BHT** |

1. **Conclusion**

We have synthesized a series of 1,2,3-triazoles linked to an diaryl sulfone moiety exploiting the click chemistry properties of the CuAAC-reaction in aqueous *tert*-butanol under ultrasound irradiation compared to silent conditions. It was observed that ultrasound irradiation improved the yields and decreased the reaction times. All new compounds were characterized by IR, 1H NMR, 13C NMR and HRMS analysis. All synthesized compounds were screened for antibacterial, antifungal and antioxidant activities. Compounds **3b**; **6b** and **9e-g** were found to be the most effective against fungal strains. Other compounds revealed good to moderate antimicrobial activity. In addition, the antioxidant activity of all compounds was measured using the DPPH free radical assay. Compound **8e** was more potent than the standard antioxidant BHT.

1. **Experimental**
   1. ***Chemistry***

*4.1.1. General*

All chemicals used in this work were purchased from Fluka, VWR or Merck and were used without purification. Melting points were determined on a Bibby Sterilin ltd electrothermal melting point apparatus and are uncorrected. Sonochemical reactions were carried out in a Branson B1510 DTH ultrasound cleaning bath (50 kHz, 245 W). The synthesis of O-propargylated compounds was carried out by BRANSON Digital Sonifier 250 (230 V, 50/60 Hz) fitted with a microtip at 40% of maximum amplitude. All reactions were monitored by thin layer chromatography using Fluka GF254 silica gel plates with detection under UV light at 254 and 360 nm. IR spectra were recorded from KBr tablets on a Perkin Elmer 2000 FTIR spectrometer. NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer at 300.13 and 75.47 MHz, at ambient temperature unless otherwise stated. 1H NMR and 13C NMR spectra were recorded in deuterated chloroform (CDCl3 ) or dimethyl sulphoxide (DMSO-d6) using TMS as internal standard. 13C chemical shifts were related to that of the solvent. High resolution Mass spectra (HRMS) were recorded on a ESI-MS Thermo LTQ Orbitrap XL (Infusion 5 L/min, resolution: 100 000 at m/z 400, ca. 10 scans/sample averaged). The CHNS elemental analyses were performed on a vario El analyser (microanalytical unit, Cairo University, Giza, Egypt). The diaryl sulfones **1a,b**, and α–bromoketones **7a-d** were prepared according to the literature [30,39].

*4.1.2. Procedure for Sonicated Reactions*

*4.1.2.1. General Procedure for Zinc-Mediated homopropargyl alochols* ***2a,b****.*

A mixture of carbonyl compound **1a** or **b** (1.0 mmol, 1.0 equiv) in THF (10.0 mL), Zn (197.9 mg, 3.0 mmol, 3.0 equiv) and ZnBr2 (76.5 mg, 0.3 mmol, 0.3 equiv) in a 50 mL Erlenmeyer flask was subjected to ultrasonic irradiation at 25-30 oC while propargyl bromide (356.9 mg, 3.0 mmol, 3.0 equiv) was slowly added dropwise. The reaction was monitored by TLC. After completion of the reaction (Reaction times as shown in Table 1) saturated aqueous NaHCO3 (4.0 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine, dried over anhydrous MgSO4, and the solvent removed under reduced pressure. The residue afforded the corresponding homopropargyl alochols **2a,b**. The products were purified by column chromatography (SiO2; ethyl acetate/petroleum ether 1:4).

*1-(4-(phenylsulfonyl)phenyl)but-3-yn-1-ol* (**2a**). White solid; mp. 110-112 oC; IR **max (cm-1): 3289 (OH), 3255 (≡CH), 2118 (C≡C), 1316, 1155 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.95-7.61 (m, 9H), 5.52 (t, *J* = 4.2 Hz, 1H, D2O-exchangeable), 4.77(t, *J* = 5.4 Hz, 1H), 2.53-2.59 (m, 2H), 2.08 (t, *J* = 3.9 Hz, 1H); 13C NMR (DMSO, 75.46 MHz)  149.8, 141.1, 139.5, 133.0, 129.2, 126.93, 126.8, 126.6, 80.7, 72.1, 70.0, 28.1; MS (ESI) *m/z* 309 [M+Na]+. HRMS (ESI) calcd. for C16H14O3S+Na [M+Na]+, 309.0556; found 309.0556.

*2-(4-(phenylsulfonyl)phenyl)pent-4-yn-2-ol* (**2b**). Pale yellow oil; IR **max (cm-1): 3503 (OH), 3296 (≡CH), 2119 (C≡C), 1307, 1156 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.97-7.61 (m, 9H), 5.50 (s, 1H, D2O-exchangeable), 2.70 (d, *J* = 2.7 Hz, 1H), 2.49 (d, *J* = 2.4 Hz, 1H), 2.08 (t, *J* = 1.35 Hz, 1H), 1.48 (s, 3H); 13C NMR (CDCl3, 75.46 MHz)  151.9, 141.5, 140.2, 133.2, 129.3, 127.7, 125.9, 79.4, 73.1, 72.4, 34.4, 29.1; MS (ESI) *m/z* 323 [M+Na]+. HRMS (ESI) calcd. for C17H16O3S+Na [M+Na]+, 323.0712; found 323.0713.

*4.1.2.2. General Procedure for the Synthesis of 1,4-disubstituted 1,2,3-triazoles* ***3a,b***

A mixture of terminal alkyne **2a** or **b** (1.0 mmol, 1.0 equiv), benzyl azide (133.2 mg, 1.0 mmol, 1.0 equiv), CuSO4.5H2O (24.9 mg, 0.1 mmol, 0.1 equiv), and sodium ascorbate (59.4 mg, 0.3 mmol, 0.3 equiv) in H2O (1.0 mL), and *tert-*butanol (2.0 mL) was sonicated at 25-30 oC while monitored by TLC. After the appropriate time (see Table 2), the mixture was extracted with ethyl acetate (4 × 10 mL). The combined organic extracts were washed with H2O, dried over anhydrous MgSO4, filtered and concentrated in *vacuo.* The crude product was purified by column chromatography (SiO2; ethyl acetate/petroleum ether 4:1) to obtain the pure product.

*2-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-(4-(phenylsulfonyl)phenyl)ethanol* (**3a**). White solid; mp. 164-166 oC; IR **max (cm-1): 3246 (OH), 1595 (C=N), 1315, 1153 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.96-7.18 (m, 14H), 7.80 (s, 1H), 5.68 (d, *J* = 4.5 Hz, 1H, D2O-exchangeable), 5.52 (s, 2H), 4.91 (t, *J* = 4.5 Hz, 1H), 2.95 (d, *J* = 6.3 Hz, 2H); 13C NMR (DMSO, 75.46 MHz)  151.4, 143.8, 141.3, 139.5, 136.3, 133.7, 129.8, 128.7, 128.0, 127.7, 127.3, 127.2, 123.4, 71.3, 52.6, 35.3; MS (ESI) *m/z* 420 [M+H]+. HRMS (ESI) calcd. for C23H22N3O3S [M+H]+, 420.1379; found 420.1379.

*1-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-ol* (**3b**). White solid; mp. 186-188 oC; IR **max (cm-1): 3496 (OH), 1596 (C=N), 1320, 1151 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.94-7.07 (m, 14H), 7.59 (s, 1H), 5.47 (s, 2H), 5.43 (s, 1H, D2O-exchangeable), 3.06 (s, 2H), 1.42 (s, 3H); 13C NMR (DMSO, 75.46 MHz)  154.5, 143.0, 141.4, 138.8, 136.4, 133.6, 129.7, 128.6, 127.9, 127.2, 126.9, 126.5, 123.8, 72.8, 52.4, 39.5, 29.4; MS (ESI) *m/z* 434 [M+H]+. HRMS (ESI) calcd. for C24H24N3O3S [M+H]+, 434.1533; found 434.1538.

*4.1.2.3. General Procedure for Synthesis of O-propargylated aryl sulfone derivatives* ***4a,b****;* ***5a,b****.*

A suspension of NaH (96.0 mg, 4.0 mmol, 4.0 equiv) in dry DMF (5.0 mL) in a 50 mL Erlenmeyer flask was added a solution of a diaryl sulfone derivative (Compounds **2a,b**; **3a,b**)(1.0 mmol, 1.0 equiv) in dry DMF (10.0 mL)at -20 oC. Then, propargyl bromide (5.0 mmol) was slowly added dropwise to the reaction mixture under sonication. The mixture was irradiated with the Branson digital sonifier 250 (Microtip, 40% maximum amplitude with pulse on = 15.0 sec, pulse off = 5.0 sec) at -20 oC for a given time (monitored by TLC) as outlined in Table 3, before the mixture was carefully quenched with H2O (20 mL) and subsequently extracted with ethyl acetate (4 × 10 mL). The combined organic layers were washed with brine and dried over anhydrous MgSO4. The solvent was removed under reduced pressure, and the crude residue obtained was purified by column chromatography (SiO2, ethyl acetate/petroleum ether 1:3) to obtain the propargyl ethers **4a,b**; **5a,b** .

*1-benzyl-4-(2-(4-(phenylsulfonyl)phenyl)-2-(prop-2-yn-1-yloxy)ethyl)-1H-1,2,3-triazole* (**4a**).White solid; mp. 118-120 oC; IR **max (cm-1): 3268 (≡CH), 2128 (C≡C), 1598 (C=N), 1318, 1160 (SO2), 1210 (C-O-C); 1H NMR (CDCl3, 300 MHz)  7.96-7.20 (m, 14H), 7.42 (s, 1H), 5.47 (s, 2H), 4.86 (t, *J* = 5.7 Hz, 1H), 4.08 (dd, *J* = 16.5, 2.4 Hz, 1H), 3.81 (dd, *J* = 16.5, 2.4 Hz, 1H), 3.19 (dd, *J* = 15.0, 8.1 Hz, 1H), 3.01 (dd, *J* = 15.0, 5.4 Hz, 1H), 2.24 (t, *J* = 1.5 Hz, 1H); 13C NMR (CDCl3, 75.46 MHz)  146.3, 143.9, 141.2, 134.8, 133.3, 129.3, 129.0, 128.6, 127.9, 127.8, 127.7, 127.6, 122.4, 79.1, 78.9, 74.9, 56.3, 54.0, 34.4; MS (ESI) *m/z* 458 [M+H]+. HRMS (ESI) calcd. for C26H24N3O3S [M+H]+, 458.1533; found 458.1535.

*1-benzyl-4-(2-(4-(phenylsulfonyl)phenyl)-2-(prop-2-yn-1-yloxy)propyl)-1H-1,2,3-triazole* (**4b**).White solid; mp. 140-142 oC; IR **max (cm-1): 3287 (≡CH), 2121 (C≡C), 1676 (C=N), 1307, 1157 (SO2), 1219 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz)  7.91-7.10 (m, 15H), 5.44 (s, 2 H), 3.91(s, 2H), 3.07 (s, 2H), 2.45 (t, br, 1H), 1.48 (s, 3H); 13C NMR (DMSO, 75.46 MHz)  150.2, 142.0, 141.1, 139.7, 136.2, 133.7, 129.8, 128.7, 127.9, 127.4, 127.3, 127.3, 123.9, 81.0, 79.5, 76.5, 52.5, 51.4, 37.6, 23.4; MS (ESI) *m/z* 472 [M+H]+. HRMS (ESI) calcd. for C27H26N3O3S [M+H]+, 472.1689; found 472.1692.

*1-(phenylsulfonyl)-4-(1-(prop-2-yn-1-yloxy)but-3-yn-1-yl)benzene* (**5a**). Pale yellow oil; IR **max (cm-1): 3288 (≡CH), 2118 (C≡C), 1307, 1155 (SO2), 1181 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz)  8.0-7.60 (m, 9H), 4.73 (t, *J* = 6.0 Hz, 1H), 4.14 (dd, *J* = 15.9, 2.4 Hz, 1H), 3.98 (dd, *J* = 16.2, 2.4 Hz, 1H), 3.47 (t, *J* = 2.4 Hz, 1H), 2.80 (t, *J* = 2.4 Hz, 1H), 2.64 (m, 2H); 13C NMR (DMSO, 75.46 MHz)  146.0, 141.0, 140.6, 133.8, 129.9, 128.1, 127.4, 80.2, 79.7, 77.7, 77.2, 73.4, 56.0, 26.2; MS (ESI) *m/z* 347 [M+Na]+. HRMS (ESI) calcd. for C19H16O3S+Na [M+Na]+, 347.0712; found 347.0714.

*1-(phenylsulfonyl)-4-(2-(prop-2-yn-1-yloxy)pent-4-yn-2-yl)benzene* (**5b**). Yellow oil; IR **max (cm-1): 3291 (≡CH), 2110 (C≡C), 1307, 1156 (SO2), 1218 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz)  7.80-7.40 (m, 9H), 3.71 (d, *J* = 6.6 Hz, 2H), 3.08 (t, *J* = 6.0 Hz, 1H), 3.02 (s, 2H), 2.89 (t, *J* = 1.8 Hz, 1H),, 1.40 (s, 3H);  13C NMR (DMSO, 75.46 MHz)  149.3, 141.0, 140.1, 133.8, 129.8, 127.4, 127.3, 80.7, 80.2, 78.7, 76.6, 73.8, 51.56, 31.45, 23.4; MS (ESI) *m/z* 361 [M+Na]+. HRMS (ESI) calcd. for C20H18O3S+Na [M+Na]+, 361.0869; found 361.0870.

*4.1.2.4. General Procedure for the Synthesis of 1,4-disubstituted 1,2,3-bistriazoles* ***6a,b***

***Route A***

In an Erlenmeyer ﬂask, a mixture of O-propargylated diaryl sulfones **4a** or **b** (1.0 mmol, 1.0 equiv), benzyl azide (133.2 mg, 1.0 mmol, 1.0 equiv), CuSO4.5H2O (24.9 mg, 0.1 mmol, 0.1 equiv), and sodium ascorbate (59.4 mg, 0.3 mmol, 0.3 equiv) in H2O (1.0 mL), and *tert-*butanol (2.0 mL) was subjected to ultrasonic irradiation at 25-30 oC for an appropriate time as outlined in Table 2(monitored by TLC), and subsequently extracted with ethyl acetate (4 × 10 mL). The combined organic extracts were washed with H2O, dried over anhydrous MgSO4, filtered and concentrated *in* *vacuo.* The crude compound was purified by column chromatography (SiO2, ethyl acetate/petroleum ether 4:1) to obtain the pure product.

***Route B***

A mixture of the bis-terminal alkyne **5a** or **b** (1.0 mmol), benzyl azide (266.4 mg, 2.0 mmol, 2.0 equiv), CuSO4.5H2O (49.8 mg, 0.2 mmol, 0.2 equiv), and sodium ascorbate (118.8 mg, 0.6 mmol, 0.6 equiv) in H2O (1.0 mL), and *tert-*butanol (2.0 mL) was subjected to the same treatment as in *Route A*.

*1-benzyl-4-((2-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-(4-(phenylsulfonyl)phenyl)ethoxy)-*

*methyl)-1H-1,2,3-triazole* (**6a**). White solid; mp. 131-133 oC; IR **max (cm-1): 1599 (C=N), 1308, 1162 (SO2), 1220 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz)  8.04 (s, 1H), 7.97-7.11 (m, 19H), 7.73 (s, 1H), 5.53 (s, 2H), 5.48 (s, 2H), 4.83 (t, *J* = 6.6 Hz, 1H), 4.36 (s, 2H), 3.06 (dd, *J* = 14.7, 8.1 Hz, 1H), 2.95 (dd, *J* = 14.4, 6.0 Hz, 1H); 13C NMR (DMSO, 75.46 MHz) 147.4, 143.8, 143.0, 141.1, 140.2, 136.3, 136.0, 133.8, 129.8, 128.8, 128.7, 128.1, 128.0, 127.9, 127.8, 127.5, 127.4, 124.1, 123.4, 79.1, 61.8, 52.7, 52.5, 33.4; MS (ESI) *m/z* 591 [M+H]+. HRMS (ESI) calcd. for C33H31N6O3S [M+H]+, 591.2173; found 591.2179.

*1-benzyl-4-(((1-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)Propan-2-yl)oxy)methyl)-1H-1,2,3-triazole* (**6b**). White solid; mp. 150-152 oC; IR **max (cm-1): 1595 (C=N), 1307, 1156 (SO2), 1219 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz)  7.94-7.10 (m, 21H), 5.48 (s, 2H), 5.43 (s, 2H), 3.06 (s, 2H), 2.07 (s, 2H), 1.42 (s, 3H); 13C NMR (CDCl3, 75.46 MHz) 150.1, 145.5, 143.1, 141.4, 140.5, 134.8, 134.5, 133.2, 129.3, 129.1, 129.0, 128.8, 128.6, 128.0, 127.7, 127.6, 127.1, 122.8, 122.1, 79.3, 57.2, 54.1, 53.8, 39.4, 23.1; MS (ESI) *m/z* 605 [M+H]+. HRMS (ESI) calcd. for C34H33N6O3S [M+H]+, 605.2329; found 605.2338.

*4.1.2.5. General Procedure for the One- pot Synthesis of 1,4-disubstituted 1,2,3-monotriazoles* ***8a-h***

To a solution of a α-bromo ketone (**7a-d)** (1.0 mmol, 1.0 equiv), NaN3 (78.01 mg, 1.2 mmol, 1.2 equiv), and terminal alkyne **2a** or **b** (1.0 mmol, 1.0 equiv) in H2O (3.0 mL), and *tert-*butanol(1.0 mL) was added CuSO4.5H2O (24.9 mg, 0.10 mmol, 0.10 equiv) and sodium ascorbate (59.4 mg, 0.30 mmol, 0.30 equiv). The reaction mixture was sonicated in the water bath of an ultrasonic cleaner at 25–30 oC until the reaction was complete, as indicated by TLC (Reaction times are given in Table 5). Then the organic phase was extracted with dichloromethane (4 × 10 mL). The combined organic extracts were washed with H2O, dried over anhydrous MgSO4, filtered and concentrated in *vacuo.* The crude product was purified by column chromatography (SiO2, dichloromethane/methanol 10:1) to obtain the pure product.

*2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenyl*

*sulfonyl)phenyl)ethanone* (**8a**). White solid; mp. 221-223 oC; IR **max (cm-1): 3417 (OH), 1713 (C=O), 1596 (C=N), 1295, 1153 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.23-7.54 (m, 18H), 7.73 (s, 1H), 6.12 (s, 2H), 5.65 (d, *J* = 4.2 Hz, 1H, D2O-exchangeable), 4.90 (t, *J* = 5.7 Hz, 1H), 2.97 (d, *J* = 6.0 Hz, 2H); 13C NMR (DMSO, 75.46 MHz)  191.8, 151.4, 145.3, 143.4, 141.3, 140.3, 139.5, 137.9, 134.2, 133.6, 129.9, 129.7,129.5, 127.9, 127.7, 127.3, 124.7, 71.3, 55.9, 35.2; MS (ESI) *m/z* 610 [M+Na]+. HRMS (ESI) calcd. for C30H25N3O6S2+Na [M+Na]+, 610.1077; found 610.1080.

*1-(4-fluorophenyl)-2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-1-yl)ethanone* (**8b**). White solid; mp. 140-142 oC; IR **max (cm-1): 3452 (OH), 1702 (C=O), 1598 (C=N), 1305, 1153 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.16-7.41 (m, 13H), 7.75 (s, 1H), 6.10 (s, 2H), 5.65 (d, *J* = 4.5 Hz, 1H, D2O-exchangeable), 4.91 (t, *J* = 5.7 Hz, 1H), 2.98 (d, *J* = 6.3 Hz, 2H); 13C NMR (DMSO, 75.46 MHz)  191.0, 165.5 (d, *J* = 251.1 Hz), 151.4, 143.3, 141.3, 139.5, 133.6, 131.2 (d, *J* = 9.6 Hz), 130.9 (d, *J* = 3.0 Hz), 129.7, 127.3, 124.8, 116.1 (d, *J* = 21.9 Hz), 71.3, 55.6, 35.2; MS (ESI) *m/z* 488 [M+Na]+. HRMS (ESI) calcd for C24H20FN3O4S+Na [M+Na]+, 488.1051; found 488.1049.

*1-(4-bromophenyl)-2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-1-yl)ethanone* (**8c**). White solid; mp. 190-192 oC; IR **max (cm-1): 3420 (OH), 1703 (C=O), 1586 (C=N), 1306, 1154 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.99-7.59 (m, 13H), 7.80 (s, 1H), 6.09 (s, 2H), 5.69 (s broad, 1H, D2O-exchangeable), 4.94 (broad, 1H), 2.99 (s broad, 2H); 13C NMR (DMSO, 75.46 MHz)  191.6, 151.4, 141.3, 139.4, 137.9, 133.6, 133.2, 132.0, 130.1, 129.7, 128.23, 127.2, 71.23, 55.6, 35.2; MS (ESI) *m/z* 548 [M+Na]+. HRMS (ESI) calcd. for C24H20BrN3O4S+Na [M+Na]+, 548.0250; found 548.0252.

*2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-1-yl)-1-phenyl*

*ethanone* (**8d**). White solid; mp. 160-162 oC; IR **max (cm-1): 3307 (OH), 1701 (C=O), 1596 (C=N), 1309, 1154 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.06-7.56 (m, 14H), 7.76 (s, 1H), 6.10 (s, 2H), 5.67 (d, *J* = 4.5 Hz, 1H, D2O-exchangeable), 4.92 (t, *J* = 6.3 Hz, 1H), 2.99 (d, *J* = 6.0 Hz, 2H); 13C NMR (DMSO, 75.46 MHz)  192.3, 151.4, 143.3, 141.3, 139.5, 134.2, 133.6, 129.8, 129.0, 128.2, 127.3, 124.9, 71.4, 55.7, 35.2; MS (ESI) *m/z* 470 [M+Na]+. HRMS (ESI) calcd. for C24H21N3O4S+Na [M+Na]+, 470.1142; found 470.1142.

*2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)propyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)phenyl)ethanone* (**8e**). White solid; mp. 205-207 oC; IR **max (cm-1): 3431 (OH), 1710 (C=O), 1595 (C=N), 1307, 1156 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.19-7.58 (m, 19H), 6.08 (s, 2H), 5.45 (s broad, 1H), 3.10 (s, 2H), 1.41 (s, 3H); 13C NMR (DMSO, 75.46 MHz)  191.8, 154.7, 145.2, 141.4, 140.2, 138.8, 137.9, 134.2, 133.6, 129.9, 129.7, 129.4, 127.9, 127.6, 127.2, 126.9, 126.5, 72.7, 55.9, 39.2, 29.2; MS (ESI) *m/z* 624 [M+Na]+. HRMS (ESI) calcd. for C31H27N3O6S2+Na [M+Na]+, 624.1233; found 624.1236.

*1-(4-fluorophenyl)-2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)propyl)-1H-1,2,3-triazol-1-yl)ethanone* (**8f**). White solid; mp. 183-185 oC; IR **max (cm-1): 3404 (OH), 1702 (C=O), 1598 (C=N), 1307, 1156 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.13-7.40 (m, 14H), 6.05 (s, 2H), 5.48 (s broad, 1H, D2O-exchangeable), 3.10 (s, 2H), 1.43 (s, 3H); 13C NMR (CDCl3, 75.46 MHz)  188.6, 166.4 (d, *J* = 256.0 Hz), 153.3, 141.4, 139.4, 133.1, 130.8 (d, *J* = 9.6 Hz), 130.2 (d, *J* = 3.0 Hz), 129.2, 127.5, 126.0, 116.3 (d, *J* = 21.9 Hz), 74.1, 55.3, 39.2, 29.8; MS (ESI) *m/z* 502 [M+Na]+. HRMS (ESI) calcd. for C25H22FN3O4S+Na [M+Na]+, 502.1207; found 502.1206.

*1-(4-bromophenyl)-2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)propyl)-1H-1,2,3-triazol-1-yl)ethanone* (**8g**). White solid; mp. 179-181 oC; IR **max (cm-1): 3418 (OH), 1702 (C=O), 1586 (C=N), 1307, 1155 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  7.96-7.59 (m, 14H), 6.04 (s, 2H), 5.45 (s, 1H, D2O-exchangeable), 3.10 (s, 2H), 1.42 (s, 3H); 13C NMR (DMSO, 75.46 MHz)  191.5, 154.7, 141.3, 138.7, 133.5, 133.2, 131.9, 130.1, 129.7, 127.2, 126.9, 126.5, 72.6, 55.4, 39.2, 29.3; MS (ESI) *m/z* 562 [M+Na]+. HRMS (ESI) calcd. for C25H22BrN3O4S+Na [M+Na]+, 562.0407; found 562.0409.

*2-(4-(2-hydroxy-2-(4-(phenylsulfonyl)phenyl)propyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone* (**8h**). White solid; mp. 140-142 oC; IR **max (cm-1): 3396 (OH), 1703 (C=O), 1596 (C=N), 1307, 1155 (SO2); 1H NMR (DMSO-*d6*, 300 MHz)  8.05-7.58 (m, 15H), 6.07 (s, 2H), 5.49 (s broad, 1H, D2O-exchangeable), 3.12 (s, 2H), 1.44 (s, 3H); 13C NMR (DMSO, 75.46 MHz)  192.2, 154.8, 141.4, 138.8, 134.2, 133.6, 129.7, 128.9, 128.1, 127.3, 126.9, 126.6, 72.8, 55.7, 39.5, 29.3; MS (ESI) *m/z* 484 [M+Na]+. HRMS (ESI) calcd for C25H23N3O4S+Na [M+Na]+, 484.1301; found 484.1300.

*4.1.2.6. General Procedure for the One- pot Synthesis of 1,4-disubstituted 1,2,3-bistriazoles* ***9a-h***

To a solution of a α-bromo ketone (**7a-d)** (2.0 mmol, 2.0 equiv), NaN3 (156.02 mg, 2.4 mmol, 2.4 equiv), and bis-terminal alkyne **5a** or **b** (1.0 mmol, 1.0 equiv) in H2O (3.0 mL), and *tert-*butanol(1.0 mL) was added CuSO4.5H2O (49.8 mg, 0.20 mmol, 0.20 equiv) and sodium ascorbate (118.8 mg, 0.60 mmol, 0.60 equiv). The reaction mixture was sonicated in the water bath of an ultrasonic cleaner at 25–30 oC until the reaction was complete, as indicated by TLC (Reaction times are given in Table 6). Then the organic phase was extracted with dichloromethane (4 × 10 mL). The combined organic extracts were washed with H2O, dried over anhydrous MgSO4, filtered and concentrated in *vacuo.* The crude product was purified by column chromatography (SiO2, dichloromethane/methanol 10:1) to obtain the pure product.

*2-(4-((2-(1-(2-oxo-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-4-yl)-1-(4-(phenylsulfonyl)phenyl)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)phenyl)*

*ethanone* (**9a**). White solid; mp. 145-147 oC; IR **max (cm-1): 1709 (C=O), 1596 (C=N), 1307, 1156 (SO2), 1222 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.21-7.56 (m broad, 29H), 6.16 (s broad, 2H), 6.11 (s broad, 2H), 4.88 (t broad, 1H), 4.43 (s broad, 2H), 3.06 (d broad, 2H). MS (ESI) *m/z* 927 [M+H]+. HRMS (ESI) calcd. for C47H39N6O9S3 [M+H]+, 927.1935; found 927.1925. Anal. calcd. for C47H38N6O9S3: C, 60.89; H, 4.13; N, 9.07; S, 10.38%. Found: C, 60.96; H, 4.10; N, 9.10; S, 10.35%.

*1-(4-fluorophenyl)-2-(4-((2-(1-(2-(4-fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-1-(4-(phenylsulfonyl)phenyl)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethanone* (**9b**). White solid; mp. 202-204 oC; IR **max (cm-1): 1700 (C=O), 1598 (C=N), 1307, 1156 (SO2), 1232 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.09-7.33 (m broad, 19H), 6.09 (s, 2H), 6.04 (s, 2H), 4.96 (t broad, 1H), 4.51 (s broad, 2H), 3.12 (s broad, 2H); 13C NMR (DMSO, 75.46 MHz, 50 °C) 189.9, 189.8, 164.9 (d, *J* = 251.9 Hz), 164.8 (d, *J* = 252.0 Hz), 146.7, 140.7, 139.8, 132.8, 130.5 (d, *J* = 9.5 Hz), 130.4 (d, *J* = 9.4 Hz), 128.9, 127.2, 126.8, 126.6, 115.3 (d, *J* = 22.0 Hz), 115.2 (d, *J* = 21.9 Hz), 78.5, 61.7, 55.1, 55.0, 32.9; MS (ESI) *m/z* 705 [M+Na]+. HRMS (ESI) calcd. for C35H28F2N6O5S+Na [M+Na]+, 705.1702; found 705.1703; Anal. calcd. for C35H28F2N6O5S: C, 61.58; H, 4.13; N, 12.31; S, 4.70%. Found: C, 61.66; H, 4.11; N, 12.29; S, 4.67%.

*1-(4-bromophenyl)-2-(4-((2-(1-(2-(4-bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-1-(4 (phenylsulfonyl)phenyl)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)ethanone* (**9c**). White solid; mp. 200-202 oC; IR **max (cm-1): 1702 (C=O), 1586 (C=N), 1306, 1154 (SO2), 1225 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  7.93-7.60 (m broad, 19H), 6.10 (s broad, 2H), 6.01 (s broad, 2H), 4.94 (t broad, 1H), 4.50 (s broad, 2H), 3.11 (d broad, 2H). MS (ESI) *m/z* 802 [M+Na]+. HRMS (ESI) calcd. for C35H28Br2N6O5S+Na [M+Na]+, 825.0101; found 825.0109; Anal. calcd. for C35H28Br2N6O5S: C, 52.25; H, 3.51; N, 10.45; S, 3.99%. Found: C, 52.20; H, 3.49; N, 10.50; S, 4.05%.

*2-(4-((2-(1-(2-oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)-1-(4-(phenylsulfonyl)*

*phenyl)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone* (**9d**). White solid; mp. 180-182 oC; IR **max (cm-1): 1701 (C=O), 1596 (C=N), 1307, 1154 (SO2), 1227 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.02-7.50 (m, 21H), 6.14 (s, 2H), 6.09 (s, 2H), 4.88 (t, *J* = 6.6 Hz, 1H), 4.49 (d, *J* = 12.0 Hz, 1H), 4.40 (d, *J* = 12.0 Hz, 1H), 3.13 (dd, *J* = 15.0, 7.5 Hz, 1H), 3.04 (dd, *J* = 15.0, 5.7 Hz, 1H); 13C NMR (DMSO, 75.46 MHz, 50 °C) 191.8, 191.6, 146.9, 143.2, 142.3, 140.6, 139.8, 133.8, 133.7, 133.6, 133.5, 133.3, 129.3, 128.5, 128.4, 127.6, 127.5, 127.1, 126.9, 125.2, 124.2, 78.5, 61.4, 55.3, 55.2, 33.1; MS (ESI) *m/z* 669 [M+Na]+. HRMS (ESI) calcd. for C35H30N6O5S+Na [M+Na]+, 669.1891; found 669.1892.

*2-(4-(((1-(1-(2-oxo-2-(4-(phenylsulfonyl)phenyl)ethyl)-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-(phenylsulfonyl)*

*phenyl)ethanone* (**9e**). White solid; mp. 220-222 oC; IR **max (cm-1): 1709 (C=O), 1595 (C=N), 1307, 1156 (SO2), 1222 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.21-7.62 (m broad, 29H), 6.12 (s broad, 2H), 6.01 (s broad, 2H), 4.43 (s broad, 2H), 3.09 (s broad, 2H), 1.61 (s broad, 3H); MS (ESI) *m/z* 941 [M+H]+. HRMS (ESI) calcd. for C48H41N6O9S3 [M+H]+, 941.2092; found 941.2082; Anal. calcd. for C48H40N6O9S3: C, 61.26; H, 4.28; N, 8.93; S, 10.22%. Found: C, 61.19; H, 4.21; N, 9.01; S, 10.25%.

*1-(4-fluorophenyl)-2-(4-(((1-(1-(2-(4-fluorophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethanone* (**9f**). White solid; mp. 210-212 oC; IR **max (cm-1): 1702 (C=O), 1598 (C=N), 1307, 1157 (SO2), 1231 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.09-7.30 (m broad, 19H), 6.18 (s broad, 2H), 6.07 (s broad, 2H), 4.44 (s broad, 2H), 3.34 (s broad, 2H), 1.62 (s broad, 3H); MS (ESI) *m/z* 719 [M+Na]+. HRMS (ESI) calcd. for C36H30F2N6O5S+Na [M+Na]+, 719.1859; found 719.1862; Anal. calcd. for C36H30F2N6O5S: C, 62.06; H, 4.34; N, 12.06; S, 4.60%. Found: C, 62.15; H, 4.31; N, 12.03; S, 4.56%.

*1-(4-bromophenyl)-2-(4-(((1-(1-(2-(4-bromophenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)ethanone* (**9g**). White solid; mp. 217-219 oC; IR **max (cm-1): 1702 (C=O), 1586 (C=N), 1306, 1156 (SO2), 1224 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  7.91-7.61 (m broad, 19H), 6.07 (s broad, 2H), 5.98 (s broad, 2H), 4.48 (s broad, 2H), 3.10 (s broad, 2H), 1.65 (s broad, 3H); MS (ESI) *m/z* 817 [M+H]+. HRMS (ESI) calcd. for C36H31Br2N6O5S [M+H]+, 817.0438; found 817.0432; Anal. calcd. for C36H30Br2N6O5S: C, 52.82; H, 3.69; N, 10.27; S, 3.92%. Found: C, 52.91; H, 3.64; N, 10.22; S, 3.97%.

*2-(4-(((1-(1-(2-oxo-2-phenylethyl)-1H-1,2,3-triazol-4-yl)-2-(4-(phenylsulfonyl)phenyl)propan-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone* (**9h**). White solid; mp. 207-209 oC; IR **max (cm-1): 1702 (C=O), 1596 (C=N), 1307, 1156 (SO2), 1227 (C-O-C); 1H NMR (DMSO-*d6*, 300 MHz, 50 °C)  8.03-7.51 (m, 21H), 6.09 (s, 2H), 5.99 (s, 2H), 4.52 (d, *J* = 12.0 Hz, 1H), 4.43 (d, *J* = 12.0 Hz, 1H), 3.27 (s, 2H), 1.64 (s, 3H); 13C NMR (DMSO, 75.46 MHz, 50 °C) 191.9, 191.8, 150.6, 144.3, 141.6, 141.1, 139.5, 134.1, 134.0, 133.8, 133.8, 133.3, 129.4, 128.7, 128.6, 127.8, 127.2, 127.0, 126.9, 125.1, 124.9, 78.7, 56.8, 55.5, 55.3, 37.6, 23.6; MS (ESI) *m/z* 683 [M+Na]+. HRMS (ESI) calcd. for C36H32N6O5S+Na [M+Na]+, 683.2047; found 683.2051.

*4.1.3. Procedure for Silent Reactions*

All previous reactions were performed with the same reactants at same temperature and same scale as shown above, but without ultrasound irradiation. The reactions were run under stirring for the appropriate time as indicated by TLC (see Tables 1,2,3,4,5 and 6). The products were obtained and purified as described for the reactions under ultrasound.

* 1. ***Biological testing***
     1. *Antimicrobial activity*

The compounds were individually tested against a panel of gram positive and gram negative bacterial pathogens, yeast and fungi. Antimicrobial tests were carried out by the agar well diffusion method [40] using 100 μL of suspension containing 1x108 CFU/mL of pathological tested bacteria and 1 x106 CFU/mL of yeast and fungi spread on nutrient agar (NA) and Sabourand dextrose agar (SDA) respectively. After the media had cooled and solidified, wells (10 mm in diameter) were made in the solidified agar and loaded with 100 μL of test compound solution; prepared by dissolving 200 mg of the chemical compound in 1 mL of dimethyl sulfoxide (DMSO). The inculcated plates were then incubated for 24 h at 37 °C for bacteria (48 h at 28 °C for fungi). Negative controls were prepared using DMSO employed for dissolving the tested compound. Ciprofloxacin (50 mg/mL) and Clotrimazole (50 mg/mL) were used as standard for antibacterial and antifungal activity respectively. After incubation time, antimicrobial activity was evaluated by measuring the zone of inhibition against the test organisms and compared with that of the standard. The observed zone of inhibition is presented in Table 7. Antimicrobial activities were expressed as inhibition diameter zones in millimeters (mm). The experiments were carried out in triplicate and the average zone of inhibition was calculated.

* + 1. *Minimum inhibitory concentration (MIC)*

The antimicrobial activity of the active compounds (having inhibition zones (IZ) ≥ 16 mm) was then evaluated using the two fold serial dilution technique [41]. Two fold serial dilutions of the test compound solutions were prepared using the proper nutrient broth. The final concentrations of the solutions were 200, 100, 50 and 25 µg/mL. Each 5 mL received 0.1 mL of the appropriate inoculum and incubated at 37 °C for 24 h (48 h at 28 °C for fungi). The lowest concentration showing no growth was taken as the minimum inhibitory concentration (MIC). The observed zones of inhibition are presented in Table 8.

* + 1. *Antioxidant activity*
       1. *DPPH free radical scavenging activity*.

The hydrogen atom or electron donation ability of the corresponding compounds was measured from the bleaching of the purple colored methanolic solution of DPPH. This spectrophotometric assay uses stable radical diphenylpicrylhydrazyl (DPPH) as a reagent. One hundred microliters of various sample concentrations were added to 5 mL of 0.004% methanolic solution of diphenylpicrylhydrazyl (DPPH). After 60 min of incubation in dark, the absorbance was read against a blank at 517 nm. Inhibition free radical DPPH in percent (I %) was calculated as in Eq (1) :

*I*% = (*Ablank* − *Asample*) / (*Ablank*) ×100 (1)

Where A*blank* is the absorbance of the control reaction (containing all reagents except the test compound), and A*sample* is the absorbance of the test sample [42,43].

For determination of IC50 (The concentration that make 50% inhibition of the DPPH color), different concentrations of the chemical compounds were dissolved in methanol to obtain final concentrations ranging from 50 to 600 μg/mL. An inhibition curve was made against concentration and IC50 was determined. All results of antioxidant activity are summarized in Table 9.

**Acknowledgments**

This work was supported by an Yggdrasil research grant from the Research Council of Norway (202902/V11) and by the Egyptian Ministry of Higher Education and State for Scientific Research with a ParOwn Research Fellowship. They are gratefully acknowledged for the financial support.

**Appendix A. Supplementary data**

1H and 13C NMR spectra of all new compounds in this article can be found in the online version, at

http://dx.doi.org/

**REFERENCES:**

|  |  |
| --- | --- |
| [1] | R.C. Moellering, Am. J. Med. 99 (1995) 11S-18S. |
| [2] | House of Lords Select Committee for Science and Technology. *Resistance to antibiotics and other antimicrobial agents*, 7th report. London: HMSO, 1998. |
| [3] | E. Leung, D.E. Weil, M. Raviglione, H. Nakatani, Bull. World Health Organ. 89 (2011) 390-392. |
| [4] | World Health Organization Division of Emerging and Other Communicable Disease Surveillance and Control. *The Medical Impact of the Use of Antimicrobials in Food Animals*. Report of a WHO Meeting. Berlin, Germany. 13-17 October 1997. WHO/EMC/ZOO/97.4; 1998. |
| [5] | M. Eberlein, K.A. Scheibner, K.E. Black, W. Willet, Science 264 (1994) 532-537. |
| [6] | K. Rais-Bahrami, M. Majd, E. Veszelovszky, B.L. Short, Am. J. Perinatol. 21 (2004) 329-332. |
| [7] | J.D. Duarte, R.M. Cooper-DeHoff, Expert Rev. Cardiovasc. Ther. 8 (2010) 793-802. |
| [8] | A. Romvary, F. Simon, Acta Vet. Hung. 40 (1992) 99-106. |
| [9] | W. Billard, H. Binch, K. Bratzler, L.Y. Chen, G. Crosby, Jr., R.A. Duffy, S. Dugar, J. Lachowicz, R. McQuade, P. Pushpavanam, V.B. Ruperto, L.A. Taylor, J.W. Clader, Bioorg. Med. Chem. Lett. 10 (2000) 2209-2212. |
| [10] | R.A. Batey, F. Huang, Tetrahedron, 63 (2007) 7667–7672. |
| [11] | V. Padmavathi, P. Thriveni, G. Sudhakar Reddy, D. Deepti, Eur. J. Med. Chem. 43 (2008) 917-924. |
| [12] | N.K. Konduru, S. Dey, M. Sajid, M. Owais, N. Ahmed, Eur. J. Med. Chem. 59 (2013) 23-30. |
| [13] | P.A. Todd, S.P. Clissold, Drugs, 41 (1991) 625-646. |
| [14] | C.R. Lee, J.A. Balfour, Drugs, 48 (1994) 907-929. |
| [15] | M.S. El-Gaby, G.A. El-Hag Ali, A.A. El-Maghraby, M.T. Abd El-Rahman, M.H. Helal, Eur. J. Med. Chem. 44 (2009) 4148-4152. |
| [16] | R. Wolf, H. Matz, E. Orion, B. Tuzun, Y. Tuzun, Dapsone, Dermatol. Online J. 8 (2002) 2. |
| [17] | G.H. Faget, R.C. Pogge, F.A. Johansen, J.F. Dinan, B.M. Prejean, C.G. Eccles, Int. J. Lepr. Other Mycobact. Dis. 34 (1966) 298-310. |
| [18] | S.F. Barbuceanu, G. Saramet, G.L. Almajan, C. Draghici, F. Barbuceanu, G. Bancescu, Eur. J. Med. Chem. 49 (2012) 417-423. |
| [19] | S.F. Barbuceanu, G.L. Almajan, I. Saramet, C. Draghici, R. Socoteanu, F. Barbuceanu, G. Bancescu, J. Serb. Chem. Soc. 74 (2009) 1041-1049. |
| [20] | S.F. Barbuceanu, G.L. Almajan, I. Saramet, C. Draghici, A.I. Tarcomnicu, G. Bancescu, Eur. J. Med. Chem. 44 (2009) 4752-4757. |
| [21] | G.L. Almajan, S.F. Barbuceanu, E.R. Almajan, C. Draghici, G. Saramet, Eur. J. Med. Chem. 44 (2009) 3083-3089. |
| [22] | G.L. Almajan, S.F. Barbuceanu, A. Innocenti, A. Scozzafava, C.T. Supuran, J. Enzyme Inhib. Med. Chem. 23 (2008) 101-107. |
| [23] | H.N. Shin, S.H. Seo, H. Choo, G. Kuem, K.I. Choi, G. Nam, Bioorg. Med. Chem. Lett. 23 (2013) 1193-1196. |
| [24] | P. Mani Chandrika, T. Yakaiah, G. Gayatri, K. Pranay Kumar, B. Narsaiah, U.S. Murthy, A. Raghu Ram Rao, Eur. J. Med. Chem. 45 (2010) 78-84. |
| [25] | A.K. Jordao, P.P. Afonso, V.F. Ferreira, M.C. de Souza, M.C. Almeida, C.O. Beltrame, D.P. Paiva, S.M. Wardell, J.L. Wardell, E.R. Tiekink, C.R. Damaso, A.C. Cunha, Eur. J. Med. Chem. 44 (2009) 3777-3783. |
| [26] | L. Deng, B. Yang, Q. He, Y. Hu, Drug. Des. Discov. 5 (2008) 225-231. |
| [27] | C. Hager, R. Miethchen, H. Reinke, J. Fluor. Chem. 104 (2000) 135–142. |
| [28] | H.C. Kolb, M.G. Finn, K.B. Sharpless, Angew. Chem. Int. Ed. Engl. 40 (2001) 2004-2021. |
| [29] | K.B. Sharpless, R. Manetsch, Expert Opin. Drug Discov. 1 (2006) 525-538. |
| [30] | M.F. Mady, A.A. El-Kateb, I.F. Zeid, K.B. Jørgensen, J. Chem. (2013) Article ID 364036. |
| [31] | N.M. Abd El-Rahman, T.S. Saleh, M.F. Mady, Ultrason. Sonochem.16 (2009) 70-74. |
| [32] | N.M. Abd El-Rahman, A.A. El-Kateb, M.F. Mady, Synth. Commun. 37 (2007) 3961-3970. |
| [33] | R.P. Tripathi, A.K. Yadav, A. Ajay, S.S. Bisht, V. Chaturvedi, S.K. Sinha, Eur. J. Med. Chem. 45 (2010) 142-148. |
| [34] | M.E. Hermes, F.D. Marsh, J. Org. Chem. 37 (1972) 2969–2979. |
| [35] | H. Bienayme, C. Hulme, G. Oddon, P. Schmitt, Chem. Eur. J. 6 (2000) 3321-3329. |
| [36] | E. Niki, Chem. Phys. Lipids 44 (1987) 227-253. |
| [37] | S.Y. Woo, J.H. Kim, M.K. Moon, S.H. Han, S.K. Yeon, J.W. Choi, B.K. Jang, H.J. Song, Y.G. Kang, J.W. Kim, J. Lee, D.J. Kim, O. Hwang, K.D. Park, J. Med. Chem. 57 (2014) 1473-1487. |
| [38] | A. Padmaja, C. Rajasekhar, A. Muralikrishna, V. Padmavathi, J. Chem. Pharm. Res. 4 (2012) 294-302. |
| [39] | J. Zou, F. Li, G. F. Tao, Chin. Chem. Lett. 20 (2009) 17–20. |
| [40] | C. Perez, M. Pauli, P. Bazevque, Acta Biol. Med. Exp. 15 (1990) 113-115 |
| [41] | A.C. Scott, Laboratory control of antimicrobial therapy, in: J.G. Collee, J.P. Duguid, A.G. Fraser, B.P. Marmion (Eds.), thirteenth ed., Mackie and MacCartney Practical Medical Microbiology, vol. 2 Churchill Livingstone, 1989, pp. 161-181. |
| [42] | M. Cuendet, K. Hostettmann, O. Potterat, Helv. Chim. Acta 80 (1997) 1144-1152. |
| [43] | M. Burits, F. Bucar, Phytother. Res. 14 (2000) 323-328. |